Gene: RNF213

57674
ALO17|C17orf27|KIAA1618|MYMY2|MYSTR|NET57
ring finger protein 213
protein-coding
17q25.3
Ensembl:ENSG00000173821 MIM:613768 Vega:OTTHUMG00000161415 UniprotKB:Q63HN8
NG_031980.2
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.001e-1 (AD)  6.850e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg21516384chr17:78233839RNF213Promoter3.960e-5Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MOV100.791
PHACTR40.787
BTN3A10.78
CFLAR0.774
ZNFX10.768
DNM20.763
PARP140.76
ARHGAP170.76
TEP10.758
UBA70.751

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CRH-0.409
OR4F29-0.347
OR4F5-0.334
GSG1-0.318
MUC12-0.313
VGF-0.309
ADRA1D-0.292
CBLN1-0.281
NPW-0.274
VIP-0.272

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether analog results in decreased expression of RNF213 mRNA"19095052
D000082AcetaminophenAcetaminophen results in decreased expression of RNF213 mRNA21420995
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of RNF213 mRNA21641981
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of RNF213 mRNA19770486
D000393Air PollutantsAir Pollutants analog results in decreased expression of RNF213 mRNA21757418
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of RNF213 mRNA24449571
D001151ArsenicArsenic affects the expression of RNF213 mRNA25304211
D001151ArsenicArsenic affects the methylation of RNF213 gene25304211
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in decreased expression of RNF213 mRNA"18687144
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of RNF213 mRNA21632981
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of RNF213 mRNA21569818
D004958EstradiolEstradiol results in increased expression of RNF213 mRNA19484750
C006780bisphenol Abisphenol A results in increased expression of RNF213 mRNA29275510
C006780bisphenol Abisphenol A affects the expression of RNF213 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of RNF213 mRNA26794494
C018475butyraldehydebutyraldehyde results in decreased expression of RNF213 mRNA26079696
D019256Cadmium ChlorideCadmium Chloride results in increased expression of RNF213 mRNA25993096
D019327Copper SulfateCopper Sulfate results in increased expression of RNF213 mRNA19549813
C029892cupric chloridecupric chloride results in decreased expression of RNF213 mRNA24650576
C000944dicrotophosdicrotophos results in increased expression of RNF213 mRNA28302478
D004041Dietary FatsDietary Fats results in increased expression of RNF213 mRNA18042831
C118739entinostatentinostat results in increased expression of RNF213 mRNA27188386
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of RNF213 mRNA22079256
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF213 mRNA22079256
D005557FormaldehydeFormaldehyde results in increased expression of RNF213 mRNA23649840
D005839GentamicinsGentamicins results in increased expression of RNF213 mRNA22061828
C010974glyphosateglyphosate results in increased expression of RNF213 mRNA25636363
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of RNF213 mRNA23086925
C410337K 7174K 7174 results in increased expression of RNF213 mRNA24086573
C029310lardlard results in increased expression of RNF213 mRNA26115784
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of RNF213 mRNA26378955
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of RNF213 mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of RNF213 mRNA"20188158
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of RNF213 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of RNF213 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of RNF213 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of RNF213 mRNA"25554681
D009532NickelNickel results in increased expression of RNF213 mRNA24768652|2558310
C029938nickel sulfatenickel sulfate results in increased expression of RNF213 mRNA22714537
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of RNF213 mRNA25729387
C030110oxaliplatinoxaliplatin results in increased expression of RNF213 mRNA25729387
D000073878Palm OilPalm Oil results in increased expression of RNF213 mRNA18042831
D010416PentachlorophenolPentachlorophenol results in increased expression of RNF213 mRNA23892564
D010936Plant ExtractsPlant Extracts results in decreased expression of RNF213 mRNA23557933
D011078Polychlorinated BiphenylsPolychlorinated Biphenyls affects the expression of RNF213 mRNA21334430
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RNF213 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of RNF213 mRNA22079256
D011192Potassium DichromatePotassium Dichromate results in increased expression of RNF213 mRNA23608068
C005556propionaldehydepropionaldehyde results in increased expression of RNF213 mRNA26079696
D011794QuercetinQuercetin results in increased expression of RNF213 mRNA21632981
D012834SilverSilver results in decreased expression of RNF213 mRNA27131904
D012999SomanSoman results in increased expression of RNF213 mRNA19281266
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of RNF213 mRNA26378955
C020806tetrabromobisphenol Atetrabromobisphenol A results in increased expression of RNF213 mRNA27914987
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of RNF213 mRNA20055451
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of RNF213 mRNA17101203
C009495titanium dioxidetitanium dioxide results in decreased expression of RNF213 mRNA27760801
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of RNF213 mRNA25729387
D019772TopotecanTopotecan results in increased expression of RNF213 mRNA25729387
D014212TretinoinTretinoin results in decreased expression of RNF213 mRNA21934132
D014212TretinoinTretinoin results in increased expression of RNF213 mRNA23724009
D014520UrethaneUrethane results in decreased expression of RNF213 mRNA28818685
D014635Valproic AcidValproic Acid results in increased expression of RNF213 mRNA19101580|2317975
D014635Valproic AcidValproic Acid results in increased methylation of RNF213 gene29154799
C025643vinclozolinvinclozolin affects the expression of RNF213 mRNA19015723
D014750VincristineVincristine results in decreased expression of RNF213 mRNA23649840
D015215Zidovudine[Zidovudine co-treated with IFNA1 protein] results in increased expression of RNF213 mRNA20370541

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004842ubiquitin-protein transferase activity-EXP19028597  
GO:0004842ubiquitin-protein transferase activity-IBA21873635  
GO:0004842ubiquitin-protein transferase activity-IDA21799892  
GO:0004842ubiquitin-protein transferase activity-TAS26766444  
GO:0016887ATPase activity-IDA21799892  24658080  26126547  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000209protein polyubiquitination-TAS-  
GO:0001525angiogenesis-IMP26126547  26278786  
GO:0002040sprouting angiogenesis-IBA21873635  
GO:0002040sprouting angiogenesis-IMP26766444  
GO:0006511ubiquitin-dependent protein catabolic process-IBA21873635  
GO:0006511ubiquitin-dependent protein catabolic process-IMP26766444  
GO:0016567protein ubiquitination-IDA21799892  
GO:0051260protein homooligomerization-IDA24658080  26126547  
GO:0051865protein autoubiquitination-IDA21799892  
GO:2000051negative regulation of non-canonical Wnt signaling pathway-IBA21873635  
GO:2000051negative regulation of non-canonical Wnt signaling pathway-IMP26766444  
GO ID GO Term Qualifier Evidence PubMed
GO:0005730nucleolus-IBA21873635  
GO:0005730nucleolus-IDA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA21799892  
GO:0005829cytosol-IBA21873635  
GO:0005829cytosol-IDA-  
GO:0005829cytosol-TAS-  
GO:0016020membrane-HDA19946888  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-983168Antigen processing: Ubiquitination & Proteasome degradationTAS
R-HSA-983169Class I MHC mediated antigen processing & presentationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27365075Frequency of RNF213 p.R4810K, a susceptibility variant for moyamoya disease, and health characteristics of carriers in the Japanese population. (2016 Sep)Cao YEnviron Health Prev Med
28414759Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease. (2017)Morimoto TPLoS One